"{\n \"business_address\": \"1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL 60064\", \n \"business_phone_no\": \"(847) 932-7900\", \n \"ceo\": \"Richard A. Gonzalez\", \n \"cik\": \"0001551152\", \n \"company_url\": \"www.abbvie.com\", \n \"employees\": 30000, \n \"entity_legal_form\": \"INCORPORATED\", \n \"entity_status\": null, \n \"hq_address1\": null, \n \"hq_address2\": null, \n \"hq_address_city\": null, \n \"hq_address_postal_code\": null, \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"Illinois\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"Delaware\", \n \"industry_category\": \"Drugs\", \n \"industry_group\": \"Drug Manufacturers - Major\", \n \"latest_filing_date\": \"2017-08-07\", \n \"legal_name\": \"AbbVie Inc.\", \n \"lei\": \"FR5LCKFTG8054YNNRU85\", \n \"long_description\": \"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; and M2Gen. The company was incorporated in 2012 and is based in North Chicago, Illinois.\", \n \"mailing_address\": \"1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL 60064\", \n \"name\": \"AbbVie Inc\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG0025Y4RY4\", \n   \"composite_figi_ticker\": \"ABBV:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG0025Y4RY4\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"ABBV:US\", \n   \"figi_uniqueid\": \"EQ0000000020553113\", \n   \"last_crsp_adj_date\": \"2017-10-12\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"ABBV\"\n  }, \n  {\n   \"composite_figi\": \"BBG003Q17NN9\", \n   \"composite_figi_ticker\": \"4AB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG003Q17NT3\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"4AB:GM\", \n   \"figi_uniqueid\": \"EQ0000000027596069\", \n   \"last_crsp_adj_date\": \"2017-10-12\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"4AB\"\n  }, \n  {\n   \"composite_figi\": \"BBG003Q17NN9\", \n   \"composite_figi_ticker\": \"4AB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG003Q17NN9\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"4AB:GR\", \n   \"figi_uniqueid\": \"EQ0000000027596069\", \n   \"last_crsp_adj_date\": \"2017-10-12\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"4AB\"\n  }, \n  {\n   \"composite_figi\": \"BBG003QC9NW3\", \n   \"composite_figi_ticker\": \"ABBV:FP\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XPAR\", \n   \"figi\": \"BBG003QC9NX2\", \n   \"figi_exch_cntry\": \"FP\", \n   \"figi_ticker\": \"ABBV:FP\", \n   \"figi_uniqueid\": \"EQ0000000027662940\", \n   \"last_crsp_adj_date\": \"2017-07-12\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XPAR\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"PAR\", \n   \"ticker\": \"ABBV\"\n  }, \n  {\n   \"composite_figi\": \"BBG003Q17NN9\", \n   \"composite_figi_ticker\": \"4AB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG003Q17NR5\", \n   \"figi_exch_cntry\": \"GY\", \n   \"figi_ticker\": \"4AB:GY\", \n   \"figi_uniqueid\": \"EQ0000000027596069\", \n   \"last_crsp_adj_date\": \"2017-10-12\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"4AB\"\n  }, \n  {\n   \"composite_figi\": \"BBG006YGVNS8\", \n   \"composite_figi_ticker\": \"ABBVEUR:XL\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XLON\", \n   \"figi\": \"BBG006YGVP21\", \n   \"figi_exch_cntry\": \"XL\", \n   \"figi_ticker\": \"ABBVEUR:XL\", \n   \"figi_uniqueid\": \"EQ0000000036980185\", \n   \"last_crsp_adj_date\": \"2015-04-13\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XLON\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"LSE\", \n   \"ticker\": \"0QCV\"\n  }, \n  {\n   \"composite_figi\": \"BBG003S01B24\", \n   \"composite_figi_ticker\": \"ABBV:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSWX\", \n   \"figi\": \"BBG003S01B42\", \n   \"figi_exch_cntry\": \"SE\", \n   \"figi_ticker\": \"ABBV:SE\", \n   \"figi_uniqueid\": \"EQ0000000027907965\", \n   \"last_crsp_adj_date\": \"2017-10-11\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSWX\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"SIX\", \n   \"ticker\": \"ABBV\"\n  }, \n  {\n   \"composite_figi\": \"BBG0043CS769\", \n   \"composite_figi_ticker\": \"ABBV*:MM\", \n   \"currency\": \"MXN\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMEX\", \n   \"figi\": \"BBG0043CS778\", \n   \"figi_exch_cntry\": \"MM\", \n   \"figi_ticker\": \"ABBV*:MM\", \n   \"figi_uniqueid\": \"EQ0000000028428870\", \n   \"last_crsp_adj_date\": \"2017-09-28\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMEX\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"MEX\", \n   \"ticker\": \"ABBV\"\n  }, \n  {\n   \"composite_figi\": \"BBG003Q17NN9\", \n   \"composite_figi_ticker\": \"4AB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG003Q17NP7\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"4AB:GF\", \n   \"figi_uniqueid\": \"EQ0000000027596069\", \n   \"last_crsp_adj_date\": \"2017-10-12\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"4AB\"\n  }, \n  {\n   \"composite_figi\": \"BBG003Q17NN9\", \n   \"composite_figi_ticker\": \"4AB:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG003Q17NV0\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"4AB:GB\", \n   \"figi_uniqueid\": \"EQ0000000027596069\", \n   \"last_crsp_adj_date\": \"2017-10-12\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"4AB\"\n  }, \n  {\n   \"composite_figi\": \"BBG003S01B24\", \n   \"composite_figi_ticker\": \"ABBV:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBRN\", \n   \"figi\": \"BBG006M73D22\", \n   \"figi_exch_cntry\": \"BW\", \n   \"figi_ticker\": \"ABBV:BW\", \n   \"figi_uniqueid\": \"EQ0000000027907965\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBRN\", \n   \"primary_listing\": false, \n   \"security_name\": \"ABBVIE INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG0025Y4RZ3\", \n   \"stock_exchange\": \"BRN\", \n   \"ticker\": \"US00287Y1091\"\n  }\n ], \n \"short_description\": \"AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.\", \n \"sic\": 2834, \n \"standardized_active\": true, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"ABBV\"\n}"